Edeplan, Press Release, 2 June 2021, at 9:15
After four years of intensive collaboration with the company’s trusted engineering and design partner, Eteplan, Neo Dynamics is introducing further development of the Neonevia Biopsy system. The system is designed to model the tissue during ultrasound and is based on an innovative, patented pulse technology that is designed to provide optimal injection control and precise diagnosis and maximum tissue volume for customized treatment for breast cancer. Neodynamics AB is a Swedish medical technology company that specializes in improving the diagnosis and treatment of cancer.
The collaboration between Edeplan and Neodynamics dates back to 2012, when Edeplan was responsible for designing and developing the company’s first biopsy system, which was completed in 2016 and used primarily in clinical research. Since 2016, Eteplan has further developed a biopsy called Neonavia in conjunction with Neodynamics, which is now being introduced in Sweden, Germany and the United Kingdom.
“Although much knowledge and design parts can be gleaned from the original version of Nionavia, our technical specification is very extensive. We, along with Etplan and our other partners, have designed a system that focuses on users and patients. Magnus Olsen, Chief Development and Operations Officer på Neodynamics.
“The rapid development of medical technology opens the door to new and more advanced technology. We are pleased to be a true pioneer in the field of neodynamics and to be a part of their journey. .The release of Neonavia is a great example of how our engineering can really make a difference. ” Morton Johnson, Regional Manager, Engineering Solutions, Edeplan Sweden.
The neonavia ultrasonic model is aimed at and consists of three components: a base unit (1), a manual drive unit (2) and three types of biopsy needles (3).
“We are very pleased with our collaboration with Edeplan, which not only provides us with a comprehensive knowledge of our company and our product, but also for a long time guided the entire design and development project in close collaboration with our own team. Product. Has always been very supportive of us in terms of regulatory issues. ” Magnus Olsen, Chief Development and Operations Officer på Neodynamics.
For more information, contact:
Michael Watten, SVP, Technical Documentation Solutions, Edeplan, Phone. +46 70 881 48 20
Outi Tornien, SVP, Marketing and Communications, Edeplan, Telephone. +358 10 307 3302
Neodynamics AB (Publi) is a Swedish medical technology company that specializes in improving the diagnosis and treatment of cancer. The company has an innovative biopsy method, Neonevia®. The biopsy system is based on patented pulse technology based on research conducted at the Karolinska Institutet in Sweden. Neonavia is evaluated to diagnose breast cancer at leading clinics in the UK, Germany and Sweden.
Neonavia is a state-of-the-art biopsy system with patented pulse technology that must be applied to an ultrasound-guided tissue sample and consists of a base unit, a cell phone, and three types of biopsy needles. Each type of needle is powered by a new pulse technology that provides highly controlled injection insertion and precise placement of the needle in the tumor, while enabling high-quality tissue sampling from the breasts and lymph nodes. The neonavia pulse biopsy system is designed to provide accurate and reliable tissue modeling for accurate diagnosis and personalized treatment for physicians and patients.
Eteplon offers solutions Software and Embedded settings, Solutions for industrial equipment and Civil Engineering, And Technical Documentation Solutions For the world’s leading companies in the manufacturing sector. Throughout the product life cycle our services focus on improving the competitiveness of our customers’ products, services and technological processes. The result of Eteplan’s innovative technology can be found in many industrial solutions and everyday products.
By 2020, Etflon had sales of around 0 260 million. The company currently has approximately 3,300 employees in Finland, Sweden, the Netherlands, Germany, Poland, Denmark and China. Edeplan’s shares are listed on Nasdaq Helsinki Limited under Tigger ETTE. www.etteplan.com